Oncodesign Precision Medicine Société anonyme Future Growth
Future criteria checks 2/6
Oncodesign Precision Medicine Société anonyme's earnings are forecast to decline at 28.8% per annum while its annual revenue is expected to grow at 50.1% per year. EPS is expected to decline by 25.9% per annum.
Key information
-28.8%
Earnings growth rate
-25.9%
EPS growth rate
Biotechs earnings growth | 22.9% |
Revenue growth rate | 50.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1 | -17 | -18 | N/A | 1 |
12/31/2025 | 14 | -7 | 13 | N/A | 2 |
12/31/2024 | 1 | -7 | -10 | N/A | 2 |
12/31/2023 | 2 | -8 | N/A | N/A | N/A |
12/31/2022 | 8 | 0 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALOPM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALOPM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALOPM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALOPM's revenue (50.1% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: ALOPM's revenue (50.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALOPM's Return on Equity is forecast to be high in 3 years time